Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Non-Cystic Fibrosis Bronchiectasis
NCT04090294Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of roflumilast in Non-cystic fibrosis bronchiectasis (NCFB), sponsored by Assiut University. Primary endpoints: Assessment of efficacy of Roflumilast regarding control of patients with non cystic fibrosis bronchiectasis at 3 months, Assessment of efficacy of roflumilast in change of performance in patients with non cystic fibrosis bronchiectasis at 3 months and 3 more. Status: unknown.
02
Drugs
roflumilast
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT04090294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090294.